Is time an important problem in management of hypertension and hypercholesterolemia by using an amlodipine-atorvastatin single pill combination?

Medical Science Monitor

Volumn 22, Issue , 2016, Pages 2648-2655

  Zeng, Rui ^a   Wang, Mian ^a   Zhang, Li ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Amlodipine; Hypercholesterolemia; Hypertension

Indexed keywords

AMLODIPINE; ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; AMLODIPINE, ATORVASTATIN DRUG COMBINATION; ANTIHYPERTENSIVE AGENT; DRUG COMBINATION; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ANKLE EDEMA; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR PARAMETERS; CASE CONTROL STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUSHING; HEADACHE; HEART LEFT VENTRICLE MASS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LEFT VENTRICULAR END DIASTOLIC DIAMETER; LEFT VENTRICULAR END DIASTOLIC VENTRICULAR SEPTAL THICKNESS; LEFT VENTRICULAR POSTERIOR WALL THICKNESS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORNING DOSAGE; PILL; SINGLE DRUG DOSE; TIME TO TREATMENT; AGED; DISEASE MANAGEMENT; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; METABOLISM; PATIENT COMPLIANCE;

ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; ATORVASTATIN CALCIUM; BLOOD PRESSURE; CASE-CONTROL STUDIES; DISEASE MANAGEMENT; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PYRROLES;

EID: 84983429847     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.896843     Document Type: Article

References (22)

1. Liu LS, Writing Group of Chinese Guidelines for the Management of H: [2010 Chinese guidelines for the management of hypertension]. Zhonghua Xin Xue Guan Bing Za Zhi, 2011; 39: 579–615 [in Chinese]
2. Glorioso N, Troffa C, Filigheddu F et al: Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension, 1999; 34: 1281–86
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med, 1998; 339: 1349–57
4. Byington RP, Davis BR, Plehn JF et al: Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation, 2001; 103: 387–92
5. Schwartz GG, Olsson AG, Ezekowitz MD et al: Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study I. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA, 2001; 285: 1711–18
6. Yu JM, Kong QY, Schoenhagen P et al: The prognostic value of long-term visit-to-visit blood pressure variability on stroke in real-world practice: A dynamic cohort study in a large representative sample of Chinese hypertensive population. Int J Cardiol, 2014; 177: 995–1000
7. Sever PS, Dahlof B, Poulter NR et al., ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo- Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet. 2003; 361: 1149–58
8. Mancia G, Laurent S, Agabiti-Rosei E et al., European Society of Hypertension: Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. J Hypertens, 2009; 27: 2121–58
9. Spencer CG, Martin SC, Felmeden DC et al: Relationship of homocysteine to markers of platelet and endothelial activation in “high risk” hypertensives: A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Int J Cardiol, 2004; 94: 293–300
10. Hu CS, Han YL, Ge JB et al: A novel management program for hypertension. Cardiovasc Diagn Ther, 2015; 5: 316–22
11. Pitt B, Byington RP, Furberg CD et al: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation, 2000; 102: 1503–10
12. Leibovitz E, Hazanov N, Zimlichman R et al: Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia. Am J Hypertens, 2001; 14: 1096–98
13. Messerli FH, Bakris GL, Ferrera D et al: Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: Results of the AVALON trial. J Clin Hypertens, 2006; 8: 571–81; quiz 582–83
14. Ikeda H, Minamikawa J, Nakamura Y et al: Comparison of effects of amlodipine and angiotensin receptor blockers on the intima-media thickness of carotid arterial wall (AAA study: amlodipine vs. ARB in atherosclerosis study). Diabetes Res Clin Pract, 2009; 83: 50–53
15. Liao JK: Endothelium and acute coronary syndromes. Clin Chem, 1998; 44: 1799–808
16. Matsuo T, Iwade K, Hirata N et al: Improvement of arterial stiffness by the antioxidant and anti-inflammatory effects of short-term statin therapy in patients with hypercholesterolemia. Heart Vessels, 2005; 20: 8–12
17. Leibovitz E, Beniashvili M, Zimlichman R et al: Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. Am J Hypertens, 2003; 16: 715–18
18. Ge CJ, Hu SJ, Wu YS, Chen NY: Effects of atorvastatin on vascular remodeling in spontaneously hypertensive rats. J Zhejiang Univ Sci, 2003; 4: 612–15
19. Fogari R, Preti P, Zoppi A et al: Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. Eur J Clin Pharmacol, 2006; 62: 817–22
20. Sugiyama M, Ohashi M, Takase H et al: Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels, 2005; 20: 133–36
21. Wassmann S, Laufs U, Baumer AT et al: HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension, 2001; 37: 1450–57
22. Nickenig G, Baumer AT, Temur Y et al: Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation, 1999; 100: 2131–34